NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Rhea-AI Summary

NRx Pharmaceuticals to present company overview at H.C. Wainwright Neuropsychiatry Virtual Conference.

Positive

• None.

Negative

• None.

RADNOR, Pa., June 20, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference. The presentation will be available for live viewing on Monday, June 26, 2023 at 9:00 a.m. ET.  Management will be available for one-on-one meetings with conference attendees as well.

A webcast and subsequent archived replay will be available on the Company's website at https://ir.nrxpharma.com/news-events/ir-calendar. The replay will be available for 90 days after the event.  

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical -stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for Suicidal Treatment-Resistant Bipolar Depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

View original content:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-present-at-the-hc-wainwright-4th-annual-neuropsychiatry-virtual-conference-301855874.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When and where will NRx Pharmaceuticals present the company overview?

NRx Pharmaceuticals will present the company overview at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on Monday, June 26, 2023 at 9:00 a.m. ET.

Will the presentation be available for live viewing?

Yes, the presentation will be available for live viewing.

How long will the replay of the webcast be available?

The replay of the webcast will be available for 90 days after the event.